Literature DB >> 16889549

Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation.

J M Saland1, S H Emre, B L Shneider, C Benchimol, S Ames, J S Bromberg, G Remuzzi, L Strain, T H J Goodship.   

Abstract

A male child initially presented with atypical hemolytic uremic syndrome (HUS) at the age of 4 months and progressed within weeks to end stage renal disease (ESRD). At the age of 2 years he received a live-related kidney transplant from his mother, which, despite initial good function, was lost to recurrent disease after 2 weeks. Complement factor H analysis showed low serum levels and the presence of two mutations on different alleles (c.2918G > A, Cys973Tyr and c.3590T > C, Val1197Ala). His survival on dialysis was at risk because of access failure and recurrent bacteremic episodes. Therefore, at the age of 5 years he received a combined liver-kidney transplant with pre-operative plasma exchange. Initial function of both grafts was excellent and this has been maintained for over 2 years. This report suggests that despite setbacks in previous experience, combined liver-kidney transplantation offers the prospect of a favorable long-term outcome for patients with HUS associated with complement factor H mutations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16889549     DOI: 10.1111/j.1600-6143.2006.01375.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  39 in total

Review 1.  What's new in haemolytic uraemic syndrome?

Authors:  Sally Johnson; C Mark Taylor
Journal:  Eur J Pediatr       Date:  2008-06-25       Impact factor: 3.183

2.  Trombotic microangiopathy: can liver-kidney transplantation cure aHUS?

Authors:  Hae Il Cheong
Journal:  Nat Rev Nephrol       Date:  2009-10       Impact factor: 28.314

3.  Recurrent atypical hemolytic uremic syndrome associated with factor I mutation in a living related renal transplant recipient.

Authors:  Micah R Chan; Christie P Thomas; Jose R Torrealba; Arjang Djamali; Luis A Fernandez; Carla J Nishimura; Richard J H Smith; Millie D Samaniego
Journal:  Am J Kidney Dis       Date:  2008-09-21       Impact factor: 8.860

4.  Hemolytic uremic syndrome due to homozygous factor H deficiency.

Authors:  Sidharth Kumar Sethi; Dragon-Durey Marie-Agnes; Neelam Thaker; Pankaj Hari; Arvind Bagga
Journal:  Clin Exp Nephrol       Date:  2009-07-01       Impact factor: 2.801

5.  Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype.

Authors:  Marina Noris; Jessica Caprioli; Elena Bresin; Chiara Mossali; Gaia Pianetti; Sara Gamba; Erica Daina; Chiara Fenili; Federica Castelletti; Annalisa Sorosina; Rossella Piras; Roberta Donadelli; Ramona Maranta; Irene van der Meer; Edward M Conway; Peter F Zipfel; Timothy H Goodship; Giuseppe Remuzzi
Journal:  Clin J Am Soc Nephrol       Date:  2010-07-01       Impact factor: 8.237

Review 6.  Guidelines for the management and investigation of hemolytic uremic syndrome.

Authors:  Takashi Igarashi; Shuichi Ito; Mayumi Sako; Akihiko Saitoh; Hiroshi Hataya; Masashi Mizuguchi; Tsuneo Morishima; Kenji Ohnishi; Naohisa Kawamura; Hirotsugu Kitayama; Akira Ashida; Shinya Kaname; Hiromichi Taneichi; Julian Tang; Makoto Ohnishi
Journal:  Clin Exp Nephrol       Date:  2014-08       Impact factor: 2.801

7.  Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome.

Authors:  Carla Nester; Zoe Stewart; David Myers; Jennifer Jetton; Ramesh Nair; Alan Reed; Christie Thomas; Richard Smith; Patrick Brophy
Journal:  Clin J Am Soc Nephrol       Date:  2011-05-26       Impact factor: 8.237

8.  Long-term successful liver-kidney transplantation in a child with atypical hemolytic uremic syndrome caused by homozygous factor H deficiency.

Authors:  Emmanuel Gonzales; Tim Ulinski; Dalila Habes; Georges Deschênes; Véronique Frémeaux-Bacchi; Albert Bensman
Journal:  Pediatr Nephrol       Date:  2016-10-15       Impact factor: 3.714

9.  Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation.

Authors:  Samhar I Al-Akash; P Stephen Almond; Van H Savell; Salam I Gharaybeh; Cris Hogue
Journal:  Pediatr Nephrol       Date:  2010-12-02       Impact factor: 3.714

10.  Liver-kidney transplantation to cure atypical HUS: still an option post-eculizumab?

Authors:  Jeffrey Saland
Journal:  Pediatr Nephrol       Date:  2013-12-22       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.